Charles River Laboratories CRL Venture Capital And Equity Method Investments, Gain (Loss) And Impairments, Net
Venture Capital And Equity Method Investments, Gain (Loss) And Impairments, Net at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept crl:VentureCapitalAndEquityMethodInvestmentsGainLossAndImpairmentsNet.
The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Charles River Laboratories's venture capital and equity method investments, gain (loss) and impairments, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Charles River Laboratories's venture capital and equity method investments, gain (loss) and impairments, net?
- Charles River Laboratories (CRL) reported venture capital and equity method investments, gain (loss) and impairments, net of -$1.14M in Q1 2026.
- How has Charles River Laboratories's venture capital and equity method investments, gain (loss) and impairments, net changed year-over-year?
- Charles River Laboratories's venture capital and equity method investments, gain (loss) and impairments, net increased by 89.0% year-over-year, from -$10.37M to -$1.14M.
- What does venture capital and equity method investments, gain (loss) and impairments, net mean?
- This metric captures the gains, losses, and impairment charges related to the company's minority equity investments in other entities. It reflects the performance of the company's strategic investment portfolio outside of its core operations. These figures are adjusted for cash flow purposes as they represent non-operating valuation changes.